XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 169,506 $ 8,988
Short-term investments – available for sale 134,656 11,587
Prepaid clinical trial and preclinical study costs 1,847 887
Prepaid expenses and other current assets 607 389
Total current assets 306,616 21,851
Deferred public offering and other financing costs 180 270
Total assets 306,796 22,121
Current liabilities:    
Accounts payable 1,215 1,529
Other accrued liabilities 3,528 2,257
Accrued interest, current   22
Convertible notes payable, current (net of discount of $0 and $404 at September 30, 2018 and December 31, 2017, respectively)   3,451
Debt conversion feature liability, current   1,398
Total current liabilities 4,743 8,657
Total liabilities 4,743 8,657
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at September 30, 2018 and December 31, 2017; no shares issued and outstanding at September 30, 2018 and December 31, 2017
Common stock, $0.00001 par value: 300,000,000 shares authorized at September 30, 2018 and December 31, 2017; 71,284,604 and 35,817,104 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 1  
Additional paid-in capital 399,847 94,339
Accumulated deficit (97,678) (80,855)
Accumulated other comprehensive loss (117) (20)
Total stockholders’ equity 302,053 13,464
Total liabilities and stockholders’ equity $ 306,796 $ 22,121